Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its consumer health division, Kenvue, JNJ has fully transitioned into a high-growth, pure-play healthcare powerhouse focused exclusively on Innovative Medicine and Medical Technology (MedTech). [...]
Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said.
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone follows a year of aggressive restructuring and a landmark "TrumpRx" partnership that has provided the company with
When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation.
The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The headline of Day 1 was undoubtedly the announcement of a massive strategic partnership between Eli Lilly and Company (NYSE:
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has been defined by the explosive rise of GLP-1 weight-loss drugs and the volatility of post-pandemic earnings, Abbott has successfully completed a pivot that many [...]
In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive agreement to acquire Ventyx Biosciences (NASDAQ: VTYX) for approximately $1.2 billion. The all-cash transaction, priced at $14.00 per share, represents
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its lead drug candidate, sonelokimab. The Swiss biotech company announced on January 8, 2026, that a successful Type B meeting with the U.
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (NYSE: ABBV) was in advanced discussions
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
The Wall Street Journal reported on Wednesday, citing people familiar with the matter, that AbbVie is in advanced talks to buy Revolution Medicines, while adding it couldn’t learn how much AbbVie is offering for the company.
